Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.59 |
| ▸ | ESR1 | P03372 | 8/20 | 0.59 |
| ▸ | IKZF2 | Q9UKS7 | 3/20 | 0.51 |
| ▸ | AR | P10275 | 3/20 | 0.46 |
| ▸ | WIZ | O95785 | 1/20 | 0.46 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.44 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22661413 | 0.92 | CRBN (0.53) | CRBNESR1IKZF2AR | |
| SCHEMBL29596996 | 0.92 | CRBN (0.53) | CRBNESR1IKZF2AR | |
| SCHEMBL27314508 | 0.92 | CRBN (0.55) | CRBNESR1IKZF2WIZCSNK1A1 | |
| SCHEMBL22661386 | 0.92 | CRBN (0.53) | CRBNESR1IKZF2AR | |
| SCHEMBL24735001 | 0.89 | WIZ (0.52) | CRBNIKZF2WIZIKZF1 | |
| SCHEMBL22581062 | 0.89 | CRBN (0.57) | CRBNESR1IKZF2ARWIZ | |
| SCHEMBL30906292 | 0.89 | CRBN (0.57) | CRBNESR1IKZF2ARWIZ | |
| SCHEMBL31047983 | 0.89 | WIZ (0.52) | CRBNIKZF2WIZIKZF1 | |
| SCHEMBL30942356 | 0.89 | CRBN (0.57) | CRBNESR1IKZF2ARWIZ | |
| SCHEMBL29841367 | 0.89 | WIZ (0.52) | CRBNIKZF2WIZIKZF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20210171470-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2021-06-10 | — | — | US | disclosed |
| US-20210040044-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas, Inc. | 2021-02-11 | — | — | US | disclosed |
| US-10844021-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | CRBN 3/4885ESR1 93/4885IKZF2 3834/4885 |
| US-20210040044-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | CRBN 3/4885ESR1 98/4885IKZF2 3840/4885 |
| US-20210171470-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | CRBN 3/4885ESR1 98/4885IKZF2 3840/4885 |
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | CRBN 3/4885ESR1 98/4885IKZF2 3840/4885 |
| US-10844021-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, ADRM1, CRBN | CRBN 3/4885ESR1 98/4885IKZF2 3840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.